CMV-MVA Triplex Vaccination of Stem Cell Donors in Preventing CMV Viremia in Participants With Allogeneic Transplant
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Clinical Trials Related to Non-Hodgkin Lymphoma
Related studies linked through entity extraction aliases.
Unicentric Retrospective Analysis of a Cohort of 602 Young Adult and Adolescent Patients (AJA), Aged 15 to 30 Years, With Haematological Malignancies, and Managed Between 2000 and 2016
- Status
- COMPLETED
- Phase
- N/A
A Study of Glofitamab in Combination With Rituximab or Obinutuzumab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP), or Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (CHP) in Participants With Non-Hodgkin Lymphomas or With DLBCL
- Status
- COMPLETED
- Phase
- PHASE1
CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced Cancers
- Status
- COMPLETED
- Phase
- PHASE1
Multi-antigen CMV-Modified Vaccinia Ankara Vaccine in Reducing CMV Related Complications in Patients With Blood Cancer Undergoing Donor Stem Cell Transplant
- Status
- WITHDRAWN
- Phase
- PHASE2
AntiCD19 Chimeric Antigen Receptor T Cells for Relapsed or Refractory Non Hodgkin Lymphoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Study of CB-103 in Adult Patients With Advanced or Metastatic Solid Tumours and Haematological Malignancies
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Phase I/II Study of Venetoclax or Lenalidomide in Combination With Ublituximab and Umbralisib in Subjects With Relapsed or Refractory CLL/SLL and NHL
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies
- Status
- COMPLETED
- Phase
- PHASE1
Use of Zarzio® in Post-autologous Stem Cell Transplantation Procedure
- Status
- COMPLETED
- Phase
- N/A
Bendamustine + Obinutuzumab Induction With Obinutuzumab Maintenance in Untreated Mantle Cell Lymphoma
- Status
- TERMINATED
- Phase
- PHASE2
A Study of PLX2853 in Advanced Malignancies.
- Status
- COMPLETED
- Phase
- PHASE1
Irradiated Donor Cells Following Stem Cell Transplant in Controlling Cancer in Patients With Hematologic Malignancies
- Status
- TERMINATED
- Phase
- EARLY_PHASE1
Dietary Milled Seed Mix in Patients With Non-Hodgkin Lymphoma
- Status
- UNKNOWN
- Phase
- NA
Pembrolizumab in Relapsed and Refractory Gray-Zone Lymphoma (GZL), Primary Central Nervous System Lymphoma (PCNSL), and Other Extranodal Diffuse Large B-cell Lymphomas
- Status
- COMPLETED
- Phase
- PHASE2
Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Chemotherapy, Total Body Irradiation, and Post-Transplant Cyclophosphamide in Reducing Rates of Graft Versus Host Disease in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
Phase 2 Study With PQR309 in Relapsed or Refractory Lymphoma Patients
- Status
- COMPLETED
- Phase
- PHASE2
Auto Stem Cell Transplant for Lymphoma Patients
- Status
- RECRUITING
- Phase
- PHASE2
Umbilical Cord Blood Transplant With Added Sugar and Chemotherapy and Radiation Therapy in Treating Patients With Leukemia or Lymphoma
- Status
- COMPLETED
- Phase
- PHASE2